Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus causing coronavirus disease 2019 (COVID-19), has affected human lives across the globe. On 11 December 2020, the US FDA granted an emergency use authorization for the first COVID-19 vaccine, and vaccines are now widely available. Undoubtedly, the emergence of these vaccines has led to substantial relief, helping alleviate the fear and anxiety around the COVID-19 illness for both the general public and clinicians. However, recent cases of vaccine complications, including myopericarditis, have been reported after administration of COVID-19 vaccines. This article discusses the cases, possible pathogenesis of myopericarditis, and treatment of the condition. Most cases were mild and should not yet change vaccine policies, although prospective studies are needed to better assess the risk–benefit ratios in different groups.

严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 是导致 2019 年冠状病毒病 (COVID-19) 的新型冠状病毒，它已经影响了全球人类的生活。2020 年 12 月 11 日，美国 FDA 授予首个 COVID-19 疫苗的紧急使用授权，疫苗现已广泛使用。毫无疑问，这些疫苗的出现大大缓解了病情，帮助减轻了公众和临床医生对 COVID-19 疾病的恐惧和焦虑。然而，最近有报道在接种 COVID-19 疫苗后出现疫苗并发症，包括心肌心包炎。本文讨论了心肌心包炎的病例、可能的发病机制和治疗方法。大多数病例是轻微的，不应改变疫苗政策，